Last 12 months
Inside the activity.
0 purchase rows · 8 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 2 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 6 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 21, 2023 Filed Feb 23, 2023 23:30 UTC |
Birkett BernardSr VP, CFO & COO
|
GrantCommon Stock | 3,614 | $306.68 | $1,108,341.52 |
DisclosureSEC source: 0001562180-23-001799 · primarydocument.xml · nonDerivative · entry 1 Birkett Bernard · CIK 0001658001 · Sr VP, CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,409 F1 · shares: 2020 PSUs (PP19) award vesting net of taxes withheld Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:29 UTC |
Winters ChadVP, CAO & Corporate Controller
|
GrantStock Options (Right to buy) · Derivative | 1,012 | $0.00 Strike: $306.68 | $0.00 |
DisclosureSEC source: 0001562180-23-001798 · primarydocument.xml · derivative · entry 2 Winters Chad · CIK 0001811424 · VP, CAO & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,012 Underlying: Stock Options (Right to Buy) · 1,012 shares Expires 2033-02-21 F2 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 21, 2024. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:29 UTC |
Winters ChadVP, CAO & Corporate Controller
|
GrantCommon Stock | 476 | $306.68 | $145,979.68 |
DisclosureSEC source: 0001562180-23-001798 · primarydocument.xml · nonDerivative · entry 1 Winters Chad · CIK 0001811424 · VP, CAO & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,458.711 F1 · shares: 2020 PSUs (PP19) award vesting net of taxes withheld Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:29 UTC |
Witherspoon CharlesVP & Treasurer
|
GrantStock Options (Right to buy) · Derivative | 780 | $0.00 Strike: $306.68 | $0.00 |
DisclosureSEC source: 0001562180-23-001797 · primarydocument.xml · derivative · entry 2 Witherspoon Charles · CIK 0001731739 · VP & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 780 Underlying: Stock Options (Right to Buy) · 780 shares Expires 2033-02-21 F2 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 21, 2024. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:29 UTC |
Witherspoon CharlesVP & Treasurer
|
GrantCommon Stock | 407 | $306.68 | $124,818.76 |
DisclosureSEC source: 0001562180-23-001797 · primarydocument.xml · nonDerivative · entry 1 Witherspoon Charles · CIK 0001731739 · VP & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,829.4979 F1 · shares: 2020 PSUs (PP19) award vesting net of taxes withheld Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:28 UTC |
Reiss-Clark CindySenior Vice President
|
GrantStock Options (Right to buy) · Derivative | 2,988 | $0.00 Strike: $306.68 | $0.00 |
DisclosureSEC source: 0001562180-23-001796 · primarydocument.xml · derivative · entry 2 Reiss-Clark Cindy · CIK 0001916513 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,988 Underlying: Stock Options (Right to Buy) · 2,988 shares Expires 2033-02-21 F2 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 21, 2024. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:28 UTC |
Reiss-Clark CindySenior Vice President
|
GrantCommon Stock | 970 | $306.68 | $297,479.60 |
DisclosureSEC source: 0001562180-23-001796 · primarydocument.xml · nonDerivative · entry 1 Reiss-Clark Cindy · CIK 0001916513 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,320.1611 F1 · shares: 2020 PSUs (PP19) award vesting net of taxes withheld Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:27 UTC |
MacKay Kimberly BanksSVP, GC & Corporate Secretary
|
GrantStock Options (Right to buy) · Derivative | 2,988 | $0.00 Strike: $306.68 | $0.00 |
DisclosureSEC source: 0001562180-23-001795 · primarydocument.xml · derivative · entry 2 MacKay Kimberly Banks · CIK 0001835699 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,988 Underlying: Stock Options (Right to Buy) · 2,988 shares Expires 2033-02-21 F2 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 21, 2024. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:27 UTC |
MacKay Kimberly BanksSVP, GC & Corporate Secretary
|
GrantCommon Stock | 327 | $306.68 | $100,284.36 |
DisclosureSEC source: 0001562180-23-001795 · primarydocument.xml · nonDerivative · entry 1 MacKay Kimberly Banks · CIK 0001835699 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 637 F1 · shares: 2020 PSUs (PP19) award vesting net of taxes withheld Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:26 UTC |
Abraham SiljiChief Digital & Trans Officer
|
GrantStock Options (Right to buy) · Derivative | 3,216 | $0.00 Strike: $306.68 | $0.00 |
DisclosureSEC source: 0001562180-23-001794 · primarydocument.xml · derivative · entry 2 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,216 Underlying: Stock Options (Right to Buy) · 3,216 shares Expires 2033-02-21 F2 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 21, 2024. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:26 UTC |
Abraham SiljiChief Digital & Trans Officer
|
GrantCommon Stock | 2,274 | $306.68 | $697,390.32 |
DisclosureSEC source: 0001562180-23-001794 · primarydocument.xml · nonDerivative · entry 1 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,475.2997 F1 · shares: 2020 PSUs (PP19) award vesting net of taxes withheld Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:24 UTC |
Favorite Annette FSr. VP Human Resources Officer
|
GrantStock Options (Right to buy) · Derivative | 2,988 | $0.00 Strike: $306.68 | $0.00 |
DisclosureSEC source: 0001562180-23-001793 · primarydocument.xml · derivative · entry 2 Favorite Annette F · CIK 0001654975 · Sr. VP Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,988 Underlying: Stock Options (Right to Buy) · 2,988 shares Expires 2033-02-21 F2 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 21, 2024. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:24 UTC |
Favorite Annette FSr. VP Human Resources Officer
|
GrantCommon Stock | 1,740 | $306.68 | $533,623.20 |
DisclosureSEC source: 0001562180-23-001793 · primarydocument.xml · nonDerivative · entry 1 Favorite Annette F · CIK 0001654975 · Sr. VP Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,876.9617 F1 · shares: 2020 PSUs (PP19) award vesting net of taxes withheld Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:24 UTC |
Green Eric MarkDirector · President & CEO
|
GrantStock Options (Right to buy) · Derivative | 29,872 | $0.00 Strike: $306.68 | $0.00 |
DisclosureSEC source: 0001562180-23-001792 · primarydocument.xml · derivative · entry 2 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,872 Underlying: Stock Options (Right to Buy) · 29,872 shares Expires 2033-02-21 F2 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 21, 2024. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:24 UTC |
Green Eric MarkDirector · President & CEO
|
GrantCommon Stock | 14,783 | $306.68 | $4,533,650.44 |
DisclosureSEC source: 0001562180-23-001792 · primarydocument.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,705.0865 F1 · shares: 2020 PSUs (PP19) award vesting net of taxes withheld Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 18:41 UTC |
Joseph MollyDirector
|
GrantPhantom Stock Unit · Derivative | 96 | $235.35 | $22,593.60 |
DisclosureSEC source: 0001562180-23-000061 · primarydocument.xml · derivative · entry 2 Joseph Molly · CIK 0001709261 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 701 Underlying: Common Stock · 96 shares Expires not disclosed F1 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. Read SEC document |
| December 05, 2022 Filed Dec 8, 2022 13:38 UTC |
Green Eric MarkDirector · President & CEO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $57.38 | $0.00 |
DisclosureSEC source: 0001562180-22-008148 · primarydocument.xml · derivative · entry 8 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,132 Underlying: Common Stock · 50,000 shares Expires 2025-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 05, 2022 Filed Dec 8, 2022 13:38 UTC |
Green Eric MarkDirector · President & CEO
|
SaleCommon Stock | 1,100 | $241.46 | $265,610.95 |
DisclosureSEC source: 0001562180-22-008148 · primarydocument.xml · nonDerivative · entry 7 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,922.0865 F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. F8 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $241.33 to $241.56, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| December 05, 2022 Filed Dec 8, 2022 13:38 UTC |
Green Eric MarkDirector · President & CEO
|
SaleCommon Stock | 9,682 | $240.73 | $2,330,774.97 |
DisclosureSEC source: 0001562180-22-008148 · primarydocument.xml · nonDerivative · entry 6 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,022.0865 F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. F7 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $240.29 to $241.27, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| December 05, 2022 Filed Dec 8, 2022 13:38 UTC |
Green Eric MarkDirector · President & CEO
|
SaleCommon Stock | 10,752 | $239.70 | $2,577,224.29 |
DisclosureSEC source: 0001562180-22-008148 · primarydocument.xml · nonDerivative · entry 5 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,704.0865 F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. F6 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $239.26 to $240.25, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| December 05, 2022 Filed Dec 8, 2022 13:38 UTC |
Green Eric MarkDirector · President & CEO
|
SaleCommon Stock | 6,312 | $238.83 | $1,507,474.76 |
DisclosureSEC source: 0001562180-22-008148 · primarydocument.xml · nonDerivative · entry 4 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,456.0865 F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. F5 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $238.26 to $239.25, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| December 05, 2022 Filed Dec 8, 2022 13:38 UTC |
Green Eric MarkDirector · President & CEO
|
SaleCommon Stock | 9,408 | $237.67 | $2,235,976.78 |
DisclosureSEC source: 0001562180-22-008148 · primarydocument.xml · nonDerivative · entry 3 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,768.0865 F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. F4 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $237.255 to $238.21, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| December 05, 2022 Filed Dec 8, 2022 13:38 UTC |
Green Eric MarkDirector · President & CEO
|
SaleCommon Stock | 6,746 | $236.95 | $1,598,456.60 |
DisclosureSEC source: 0001562180-22-008148 · primarydocument.xml · nonDerivative · entry 2 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,176.0865 F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. F3 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $236.255 to $237.245, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| December 05, 2022 Filed Dec 8, 2022 13:38 UTC |
Green Eric MarkDirector · President & CEO
|
Exercise / conversionCommon Stock | 50,000 | $57.38 | $2,869,000.00 |
DisclosureSEC source: 0001562180-22-008148 · primarydocument.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,922.0865 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The shares reported were acquired by the Reporting Person from exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 9/14/2022. Read SEC document |
| October 31, 2022 Filed Nov 1, 2022 18:59 UTC |
Winters ChadVP, CAO & Corporate Controller
|
Tax withholdingCommon Stock | 47 | $225.51 | $10,598.97 |
DisclosureSEC source: 0001562180-22-007398 · primarydocument.xml · nonDerivative · entry 1 Winters Chad · CIK 0001811424 · VP, CAO & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 982.711 F1 · kind: Shares withheld solely for the purpose of satisfying tax liability on dividend accrued on restricted stock award vested on 10/31/2022. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 18:45 UTC |
Joseph MollyDirector
|
GrantPhantom Stock Unit · Derivative | 91 | $246.08 | $22,393.28 |
DisclosureSEC source: 0001562180-22-006970 · primarydocument.xml · derivative · entry 2 Joseph Molly · CIK 0001709261 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 605 Underlying: Common Stock · 91 shares Expires not disclosed F1 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. Read SEC document |
| August 02, 2022 Filed Aug 3, 2022 19:24 UTC |
Birkett BernardSr VP, CFO & COO
|
SaleCommon Stock | 1,100 | $343.38 | $377,722.95 |
DisclosureSEC source: 0001562180-22-005857 · primarydocument.xml · nonDerivative · entry 4 Birkett Bernard · CIK 0001658001 · Sr VP, CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 795 F4 · price: The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $343.31 to $343.67, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| August 02, 2022 Filed Aug 3, 2022 19:24 UTC |
Birkett BernardSr VP, CFO & COO
|
SaleCommon Stock | 2,007 | $342.59 | $687,573.51 |
DisclosureSEC source: 0001562180-22-005857 · primarydocument.xml · nonDerivative · entry 3 Birkett Bernard · CIK 0001658001 · Sr VP, CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,895 F3 · price: The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $342.28 to $342.93, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| August 02, 2022 Filed Aug 3, 2022 19:24 UTC |
Birkett BernardSr VP, CFO & COO
|
SaleCommon Stock | 1,708 | $341.97 | $584,083.22 |
DisclosureSEC source: 0001562180-22-005857 · primarydocument.xml · nonDerivative · entry 2 Birkett Bernard · CIK 0001658001 · Sr VP, CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,902 F2 · price: The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $341.2700 to $342.2600, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| August 02, 2022 Filed Aug 3, 2022 19:24 UTC |
Birkett BernardSr VP, CFO & COO
|
SaleCommon Stock | 9,359 | $340.50 | $3,186,694.58 |
DisclosureSEC source: 0001562180-22-005857 · primarydocument.xml · nonDerivative · entry 1 Birkett Bernard · CIK 0001658001 · Sr VP, CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,610 F1 · price: The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $340.1950 to $340.8100, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| August 01, 2022 Filed Aug 2, 2022 17:25 UTC |
Lockhart Stephen HDirector
|
GrantCommon Stock | 454 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-22-005806 · primarydocument.xml · nonDerivative · entry 1 Lockhart Stephen H · CIK 0001856013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454 F1 · price: These shares of restricted stock units will vest in full on the day of the 2023 Annual Shareholders Meeting. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 16:25 UTC |
Abraham SiljiChief Digital & Trans Officer
|
SaleCommon Stock | 5,374 | $343.93 | $1,848,306.15 |
DisclosureSEC source: 0001562180-22-005843 · primarydocument.xml · nonDerivative · entry 1 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,201.2997 F1 · price: The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $343.69 to $344.10, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 18:52 UTC |
Joseph MollyDirector
|
GrantPhantom Stock Unit · Derivative | 74 | $302.37 | $22,375.38 |
DisclosureSEC source: 0001562180-22-005438 · primarydocument.xml · derivative · entry 2 Joseph Molly · CIK 0001709261 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205 Underlying: Common Stock · 74 shares Expires not disclosed F1 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 14:12 UTC |
Birkett BernardSr VP, CFO & COO
|
Tax withholdingCommon Stock | 946 | $288.53 | $272,949.38 |
DisclosureSEC source: 0001562180-22-005321 · primarydocument.xml · nonDerivative · entry 1 Birkett Bernard · CIK 0001658001 · Sr VP, CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,969 F1 · kind: Shares withheld solely for the purpose of satisfying tax liability due upon vesting of restricted stock award. Read SEC document |
| May 24, 2022 Filed May 26, 2022 19:50 UTC |
Joseph MollyDirector
|
GrantCommon Stock | 632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-22-004434 · primarydocument.xml · nonDerivative · entry 1 Joseph Molly · CIK 0001709261 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 940 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document |
| May 24, 2022 Filed May 26, 2022 19:50 UTC |
FRIEL ROBERT FDirector
|
GrantCommon Stock | 632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-22-004433 · primarydocument.xml · nonDerivative · entry 1 FRIEL ROBERT F · CIK 0001224110 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,430.98 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document |
| May 24, 2022 Filed May 26, 2022 19:49 UTC |
Feehery William FDirector
|
GrantCommon Stock | 632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-22-004432 · primarydocument.xml · nonDerivative · entry 1 Feehery William F · CIK 0001543193 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,112.13 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document |
| May 24, 2022 Filed May 26, 2022 19:49 UTC |
Hofmann Thomas WDirector
|
GrantCommon Stock | 632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-22-004431 · primarydocument.xml · nonDerivative · entry 1 Hofmann Thomas W · CIK 0001174597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,212.39 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document |
| May 24, 2022 Filed May 26, 2022 19:49 UTC |
Pucci PaoloDirector
|
GrantCommon Stock | 632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-22-004430 · primarydocument.xml · nonDerivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,695.95 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document |
| May 24, 2022 Filed May 26, 2022 19:49 UTC |
LAI GOLDMAN MYLADirector
|
GrantCommon Stock | 632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-22-004429 · primarydocument.xml · nonDerivative · entry 1 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,172.93 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document |
| May 24, 2022 Filed May 26, 2022 19:48 UTC |
BUTHMAN MARK ADirector
|
GrantCommon Stock | 632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-22-004428 · primarydocument.xml · nonDerivative · entry 1 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,606.29 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document |
| May 24, 2022 Filed May 26, 2022 19:48 UTC |
Michels Douglas ADirector
|
GrantCommon Stock | 632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-22-004427 · primarydocument.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,920.05 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document |
| May 24, 2022 Filed May 26, 2022 19:48 UTC |
Keller Deborah LDirector
|
GrantCommon Stock | 632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-22-004426 · primarydocument.xml · nonDerivative · entry 1 Keller Deborah L · CIK 0001352992 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,405.72 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document |
| May 23, 2022 Filed May 25, 2022 19:28 UTC |
Birkett BernardSr VP, CFO & COO
|
GrantStock Options (Right to buy) · Derivative | 1,344 | $0.00 Strike: $303.34 | $0.00 |
DisclosureSEC source: 0001562180-22-004382 · primarydocument.xml · derivative · entry 1 Birkett Bernard · CIK 0001658001 · Sr VP, CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,344 Underlying: Stock Options (Right to Buy) · 1,344 shares Expires 2032-05-23 F1 · derivative.exercise_date: This award vests in four equal annual installments beginning on May 23, 2023. Read SEC document |
| May 05, 2022 Filed May 6, 2022 15:28 UTC |
Winters ChadVP, CAO & Corporate Controller
|
Tax withholdingCommon Stock | 10 | $314.76 | $3,147.60 |
DisclosureSEC source: 0001562180-22-003850 · primarydocument.xml · nonDerivative · entry 1 Winters Chad · CIK 0001811424 · VP, CAO & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,062.777 F1 · kind: Shares withheld solely for the purpose of satisfying tax liability on dividend accrued on restricted stock award vested on 5/5/2022. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 20:05 UTC |
ZENNER PATRICK JDirector
|
GrantPhantom Stock Unit · Derivative | 49 | $410.71 | $20,124.79 |
DisclosureSEC source: 0001562180-22-003058 · primarydocument.xml · derivative · entry 2 ZENNER PATRICK J · CIK 0001139036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,928.2996 Underlying: Common Stock · 49 shares Expires not disclosed F1 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 19:57 UTC |
Joseph MollyDirector
|
GrantPhantom Stock Unit · Derivative | 55 | $410.71 | $22,589.05 |
DisclosureSEC source: 0001562180-22-003057 · primarydocument.xml · derivative · entry 2 Joseph Molly · CIK 0001709261 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131 Underlying: Common Stock · 55 shares Expires not disclosed F1 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 15:16 UTC |
Lai Quintin JVP Corp Development & Strategy
|
Exercise / conversionStock Options (Right to buy) · Derivative | 5,576 | $0.00 Strike: $83.47 | $0.00 |
DisclosureSEC source: 0001562180-22-002665 · primarydocument.xml · derivative · entry 12 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,064 Underlying: Common Stock · 5,576 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 15:16 UTC |
Lai Quintin JVP Corp Development & Strategy
|
Exercise / conversionStock Options (Right to buy) · Derivative | 2,440 | $0.00 Strike: $94.27 | $0.00 |
DisclosureSEC source: 0001562180-22-002665 · primarydocument.xml · derivative · entry 11 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,640 Underlying: Common Stock · 2,440 shares Expires 2027-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 15:16 UTC |
Lai Quintin JVP Corp Development & Strategy
|
SaleCommon Stock | 200 | $374.92 | $74,984.00 |
DisclosureSEC source: 0001562180-22-002665 · primarydocument.xml · nonDerivative · entry 10 Lai Quintin J · CIK 0001744326 · VP Corp Development & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,371.8424 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.